News & Updates

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.

Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.

Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.

In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.

The survival benefit derived from using immune checkpoint inhibitors (ICIs) is more evident in patients with advanced nonsmall cell lung cancer (NSCLC) who received first-line therapy, showed low neutrophil/lymphocyte ratio (NLR), and had no history of hormone use following initial treatment, suggests a recent study.